Skip to main content
. 2015 Dec 1;56(13):7679–7686. doi: 10.1167/iovs.15-18015

Figure 4.

Figure 4

Macular thickness as assessed using SD-OCT. There is no significant difference between the vehicle-injected and the ranibizumab-treated eyes in the rate of development or severity of macular edema or the rate or severity of subsequent macular thinning in any of the three animals assessed (A1, O1, S1).